CGClaudie Gabillard-Lefort

Claudie Gabillard-Lefort

*This is an algorithmically generated author record based on publicly available information.

Claudie Gabillard-Lefort has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • CFTR modulator therapy impacts neutrophil CD39 expression in cystic fibrosis

    by Debananda Gogoi, Claudie Gabillard-Lefort, Rory Baird, Luke Forde, Mengxin Niu, Sara Waqas Ahmed, Cedric Gunaratnam, Michael Williamson, Michelle Casey, Emer P Reeves


  • Open Access

    Adaptive remodeling of rat adrenomedullary stimulus-secretion coupling in a chronic hypertensive environment

    by Vincent Paillé, Joohee Park, Bertrand Toutain, Jennifer Bourreau, Pierre Fontanaud, Frédéric De Nardi, Claudie Gabillard-Lefort, Dimitri Bréard, David Guilet, Daniel Henrion, et al.

    Chronic elevated blood pressure impinges on the functioning of multiple organs and therefore harms body homeostasis. Elucidating the protective mechanisms whereby the organism copes with sustained or repetitive blood pressure rises is therefore a topical challenge. Here we address this issue in the adrenal medulla, the master neuroendocrine tissue involved in the secretion of catecholamines, influential hormones in blood pressure regulation. Combining electrophysiological techniques with catecholamine secretion assays on acute adrenal slices from spontaneously hypertensive rats, we show that chromaffin cell stimulus-secretion coupling is remodeled, resulting in a less efficient secretory function primarily upon sustained cholinergic challenges. The remodeling is supported by revamped both cellular and tissular mechanisms. This first includes a decrease in chromaffin cell excitability in response to sustained electrical stimulation. This hallmark was observed both experimentally and in a computational chromaffin cell model, and occurs with concomitant changes in voltage-gated ion channel expression. The cholinergic transmission at the splanchnic nerve-chromaffin cell synapses and the gap junctional communication between chromaffin cells are also weakened. As such, by disabling its competence to release catecholamines in response sustained stimulations, the hypertensive medulla has elaborated an adaptive shielding mechanism against damaging effects of redundant elevated catecholamine secretion and associated blood pressure.


  • Open Access

    Adaptive remodeling of rat adrenomedullary stimulus-secretion coupling in response to a chronic hypertensive environment

    by Vincent Paillé, Joohee Park, Bertrand Toutain, Jennifer Bourreau, Pierre Fontanaud, Frédéric De Nardi, Claudie Gabillard-Lefort, Dimitri Bréard, David Guilet, Daniel Henrion, et al.

    Summary: Chronic elevated blood pressure impinges on the functioning of multiple organs and therefore harms body homeostasis. Elucidating the protective mechanisms whereby the organism copes with sustained or repetitive blood pressure rises is therefore a topical challenge. Here we address this issue in the adrenal medulla, the master neuroendocrine tissue involved in the secretion of catecholamines, influential hormones in blood pressure regulation. Using acute adrenal slices from spontaneously hypertensive rats, we show that chromaffin cell stimulus-secretion coupling is remodeled, resulting in a less efficient secretory function primarily upon sustained electrical or cholinergic challenges. The remodeling is supported by revamped cellular and tissular mechanisms, including chromaffin cell excitability through voltage-gated ion channel expression changes, gap junctional communication and cholinergic synaptic transmission. As such, by weakening its competence to release catecholamines, the ‘hypertensive medulla’ has elaborated an adaptive shielding mechanism against damaging effects of redundant elevated catecholamine secretion and associated blood pressure.

  • Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis

    by Claudie Gabillard-Lefort, Michelle Casey, Arlene M. A. Glasgow, Fiona Boland, Orla Kerr, Elaine Marron, Anne-Marie Lyons, Cedric Gunaratnam, Noel G. McElvaney, Emer P. Reeves

    Rationale: Cystic fibrosis (CF) is caused by mutations in the CFTR (CF transmembrane conductance regulator) gene and is characterized by sustained inflammation. ATP triggers IL-1β secretion via P2X7R (P2X7 receptor) and activation of the NLRP3 (NOD-, LRR-, and pyrin domain–containing protein 3) inflammasome. Objectives: To explore the effect of the CFTR modulator elexacaftor/tezacaftor/ivacaftor (Trikafta) on CFTR expression and the ATP/P2X7R signaling axis in monocytes and on circulating proinflammatory markers. Methods: Inflammatory mediators were detected in blood from 42 patients with CF before and after 3 months of Trikafta therapy. Markers of inflammasome activation and IL-1β secretion were measured in monocytes before and after stimulation with ATP and LPS, in the presence or absence of the P2X7R inhibitor A438079. Measurements and Main Results: P2X7R is overexpressed in CF monocytes, and receptor inhibition decreased NLRP3 expression, caspase-1 activation, and IL-1β secretion. In vitro and in vivo, P2X7R expression is regulated by CFTR function and intracellular chloride (Cl−) levels. Trikafta therapy restored CFTR expression yet decreased P2X7R in CF monocytes, resulting in normalized Cl− and potassium efflux, and reduced intracellular calcium levels. CFTR modulator therapy decreased circulating levels of ATP and LPS and reduced inflammasome activation and IL-1β secretion. Conclusions: P2X7R expression is regulated by intracellular Cl− levels and in CF monocytes promotes inflammasome activation. Trikafta therapy significantly increased CFTR protein expression and reduced ATP/P2X7R–induced inflammasome activation. P2X7R may therefore be a promising target for reducing inflammation in patients with CF who are noneligible for Trikafta or other CFTR modulator therapy.